- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04914377
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants (BOSS)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TQ Formula in Treating Participants Who Have Tested Positive for Novel Coronavirus 2019 (BOSS-Covid-19)
This is a randomized (1:1), double-blind, placebo-controlled phase 2 study to assess safety and efficacy of Total TQ Formula (3 g daily dose of Nigella Sativa Oil) capsules versus placebo in treating patients who have tested positive for novel Coronavirus 2019 (Covid-19) in the outpatient setting.
Patients will be treated at a dose of 500 mg, 3 capsules, two times a day for 14 days from date of randomization. Quantitative viral load as measured by RT-PCR will be evaluated at baseline and on days 7 and 14. Covid-19 symptoms will be measured throughout the study using Modified FLU-PRO Plus.
Panoramica dello studio
Descrizione dettagliata
Study Population: Up to 60 participants will be randomized 1:1 to receive either TQ Formula Capsules + Standard of Care (SOC) or placebo +SOC
Phase: Phase II
Approximately 2-4 centers in the United States
TQ Formula (Nigella Sativa) 500 mg, 3 capsules, BID, taken orally
Study Duration: 6 months
Participant Duration: Up to 45 days
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
California
-
San Diego, California, Stati Uniti, 92108
- RESPIRE Research
-
-
Florida
-
Hialeah, Florida, Stati Uniti, 33018
- L & A Morales Healthcare
-
-
Texas
-
Houston, Texas, Stati Uniti, 77054
- United Memorial Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18 and over, presenting with recent mild to moderate clinical symptoms of Covid-19 infection (per FDA guidance - see appendix 3)
- Positive COVID-19 infection confirmed with a rapid antigen test at screening (or RT-PCR within the last 3 days) and confirmed with a RT-PCR test at baseline
- A score of >/=3 on a minimum of 2 symptoms on the Modified FLU-PRO Plus
- Ability to take oral medication and be willing to adhere to the dosing regimen (Twice a day - BID for 14 days)
- For females of reproductive potential: negative pregnancy test at screening and use of highly effective contraception method during study participation and for an additional 4 weeks after the end of study drug administration
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation
- Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration
Exclusion Criteria:
- Current or recent (within 4 weeks) treatment with any corticosteroids; however, high-dose inhaled steroids, which are used to treat acute or chronic bronchial inflammation, will be permitted
- Current or recent (within 4 weeks) treatment with any antivirals
- Room air oxygen saturation (SaO2) < 94% at screen
- Walking oximetry < 90% or participant unable to complete 6-minute walking oximetry test at screen
- Severe Covid-19 symptoms (severe per FDA classification - see appendix 3)
- Requires immediate admission to hospital for any reason
- Pregnancy or lactation
- Known allergic reactions to components of black seed oil, or thymoquinone
- Treatment with another investigational drug or other investigational intervention within 2 weeks of study start and throughout study duration.
- Significant hepatic disease (ALT/AST> 4 times the ULN); any laboratory parameter >/= 4 times the ULN
- History of moderate to severe CKD, (i.e. an estimated glomerular filtration rate less than 45 mL/min) at the time of enrollment or history of liver disease
- Patients with inflammatory bowel disease (such as Crohn's) that could affect the intestinal absorption of TQ Formula enteric coated capsules.
- Known HIV or Hepatitis C infection
- Influenza diagnosis (confirmed by testing) during screening or within prior 14 days
- Any uncontrolled condition(s) or diagnosis, both physical or psychological, or physical exam finding that precludes participation, as per investigator
- Current treatment with CYP2C9 substrates
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Active Drug
Capsules containing TQ Formula
|
TQ Formula will be administered as an oral dose daily.
The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).
Altri nomi:
|
Comparatore placebo: Placebo
Capsules containing corn oil
|
TQ Formula will be administered as an oral dose daily.
The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Median Time to Sustained Clinical Response
Lasso di tempo: 21 Days
|
Measurement of the difference in median time to sustained clinical response in participants taking 3 g TQ Formula (500 mg per capsule, 3 capsules BID) versus participants taking placebo.
Sustained clinical response is defined as a reduction of scores to </= 2 on all symptoms of the Modified FLU-PRO Plus.
|
21 Days
|
Safety of Investigational Product
Lasso di tempo: Day 45
|
Number of overall adverse events, related adverse reactions, and hospitalizations reported in participants taking 3 g TQ Formula (500 mg per capsule, 3 capsules BID) versus participants taking placebo.
All AEs/SAEs will be captured throughout the study as per schedule of assessments.
|
Day 45
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in Quantitative Viral Load
Lasso di tempo: 14 Days
|
Measurement of change in quantitative viral load from baseline, Day 7, and Day 14 using RT-PCR in participants taking 3 g TQ Formula (500 mg per capsule, 3 capsules BID) versus participants taking placebo with COVID-19 infection.
|
14 Days
|
Viral Clearance
Lasso di tempo: 14 Days
|
Percentage of negative/undetectable RT-PCR (i.e., viral clearance) on Day-7 and Day-14 in participants taking 3 g TQ Formula (500 mg per capsule, 3 capsules BID) versus participants taking placebo
|
14 Days
|
Severity and Change in Covid Symptoms
Lasso di tempo: 14 Days
|
Measurement of severity of, and change in, Covid-19 symptoms per total score as well as sub-scores (Nose, Throat, Eyes, Chest/Respiratory, Gastrointestinal, Body/Systemic, Taste/Smell) measured through Modified FLU-PRO Plus from Day 1 through Day 14 in participants with COVID-19 infection treated either with 3 g TQ Formula (500 mg per capsule, 3 capsules BID) or placebo.
|
14 Days
|
Correlation between Covid Symptoms and Viral Load
Lasso di tempo: 14 Days
|
Correlation Coefficient of quantitative viral load and symptom severity at baseline, at Day 7, and Day 14 in participants taking 3 g TQ Formula (500 mg per capsule, 3 capsules BID) versus participants taking placebo
|
14 Days
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Ahmed Kaseb, MD, Novatek Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- BOSS-001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Periodo di condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Covid19
-
Anavasi DiagnosticsNon ancora reclutamento
-
Ain Shams UniversityReclutamento
-
Israel Institute for Biological Research (IIBR)Completato
-
Colgate PalmoliveCompletato
-
Christian von BuchwaldCompletato
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdAttivo, non reclutante
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichIscrizione su invito
-
Alexandria UniversityCompletato
Prove cliniche su TQ Formula/Tab
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Reclutamento
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.SconosciutoLinfoma periferico a cellule TCina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.SconosciutoCarcinoma polmonare non a piccole cellule (NSCLC) positivo per ROS1Cina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sconosciuto
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sconosciuto
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sconosciuto
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.ReclutamentoLinfoma recidivato o refrattario o cancro avanzatoCina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completato
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.SconosciutoTumore maligno avanzatoCina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sconosciuto